A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Ruth Plummer(Newcastle University), Paul Lorigan(The Christie Hospital), Neil Steven, Lucy Scott(Beatson West of Scotland Cancer Centre), Mark R. Middleton(Churchill Hospital), Richard H. Wilson(Queen's University Belfast), Evan A. Mulligan(Newcastle University), Nicola J. Curtin(Newcastle University), Diane Wang(Pfizer (United States)), R. Dewji(Pfizer (United Kingdom)), Antonello Abbattista(Pfizer (Italy)), Jorge D. Gallo(Pfizer (Italy)), Hilary Calvert(Newcastle University)
Cited by 177
Abstract
Related Papers
No related papers found
Powered by citation graph analysis